Eyestem is advancing its experimental treatment for dry age-related macular degeneration (dry AMD), backed by an underlying vision to develop a scalable cell therapy platform to treat incurable diseases and democratize access to these newer technologies.
In an interview with Scrip, the Indian cell therapy firm’s founder and CEO, Dr Jogin Desai, said that he’s "very...